246 related articles for article (PubMed ID: 11320682)
1. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.
McIntyre RS; McCann SM; Kennedy SH
Can J Psychiatry; 2001 Apr; 46(3):273-81. PubMed ID: 11320682
[TBL] [Abstract][Full Text] [Related]
2. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
Newcomer JW
CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
[TBL] [Abstract][Full Text] [Related]
3. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
[TBL] [Abstract][Full Text] [Related]
4. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
5. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
Baptista T; Kin NM; Beaulieu S; de Baptista EA
Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
[TBL] [Abstract][Full Text] [Related]
6. Atypical antipsychotics and glucose homeostasis.
Bergman RN; Ader M
J Clin Psychiatry; 2005 Apr; 66(4):504-14. PubMed ID: 15816794
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic medication: effects on regulation of glucose and lipids.
Kato MM; Goodnick PJ
Expert Opin Pharmacother; 2001 Oct; 2(10):1571-82. PubMed ID: 11825300
[TBL] [Abstract][Full Text] [Related]
8. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults.
Citrome L; Kalsekar I; Baker RA; Hebden T
Curr Med Res Opin; 2014 Aug; 30(8):1629-41. PubMed ID: 24666104
[TBL] [Abstract][Full Text] [Related]
9. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
10. Risk of diabetes mellitus associated with atypical antipsychotic use among Medicaid patients with bipolar disorder: a nested case-control study.
Guo JJ; Keck PE; Corey-Lisle PK; Li H; Jiang D; Jang R; L'Italien GJ
Pharmacotherapy; 2007 Jan; 27(1):27-35. PubMed ID: 17192159
[TBL] [Abstract][Full Text] [Related]
11. Hyperglycemia and antipsychotic medications.
Haupt DW; Newcomer JW
J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
[TBL] [Abstract][Full Text] [Related]
12. No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease.
Rondanelli M; Sarra S; Antoniello N; Mansi V; Govoni S; Falvo F; Solerte SB; Ferrari E
Minerva Med; 2006 Apr; 97(2):147-51. PubMed ID: 16760853
[TBL] [Abstract][Full Text] [Related]
13. The implications of weight changes with antipsychotic treatment.
Sussman N
J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S21-6. PubMed ID: 12832946
[TBL] [Abstract][Full Text] [Related]
14. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications.
Melkersson K; Dahl ML
Drugs; 2004; 64(7):701-23. PubMed ID: 15025545
[TBL] [Abstract][Full Text] [Related]
15. [Schizophrenia, diabetes mellitus and antipsychotics].
Gury C
Encephale; 2004; 30(4):382-91. PubMed ID: 15538314
[TBL] [Abstract][Full Text] [Related]
16. Guidelines for prevention and treatment of adverse effects of antipsychotic drugs on glucose-insulin homeostasis and lipid metabolism.
Melkersson KI; Dahl ML; Hulting AL
Psychopharmacology (Berl); 2004 Aug; 175(1):1-6. PubMed ID: 15221198
[TBL] [Abstract][Full Text] [Related]
17. [Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].
Ruetsch O; Viala A; Bardou H; Martin P; Vacheron MN
Encephale; 2005; 31(4 Pt 1):507-16. PubMed ID: 16389718
[TBL] [Abstract][Full Text] [Related]
18. Metabolic effects of antipsychotics in prepubertal children: a retrospective chart review.
Ebert T; Midbari Y; Shmilovitz R; Kosov I; Kotler M; Weizman A; Ram A
J Child Adolesc Psychopharmacol; 2014 May; 24(4):218-22. PubMed ID: 24816004
[TBL] [Abstract][Full Text] [Related]
19. Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.
Smith RC; Segman RH; Golcer-Dubner T; Pavlov V; Lerer B
Pharmacogenomics J; 2008 Jun; 8(3):228-36. PubMed ID: 17726453
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism.
eder-Ischia U; Ebenbichler C; Fleischhacker WW
Essent Psychopharmacol; 2005; 6(2):112-7. PubMed ID: 15765795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
